Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
11.47
-0.02 (-0.17%)
At close: Mar 24, 2026, 4:00 PM EDT
11.49
+0.02 (0.17%)
After-hours: Mar 24, 2026, 4:10 PM EDT
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Entrada Therapeutics stock have an average target of 20, which predicts a 74.37% increase from the current stock price of 11.47.
Price Target: $20 (+74.37%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 18, 2026.
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +74.37% | Feb 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +74.37% | Feb 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +74.37% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +74.37% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +74.37% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
35.58M
from 25.42M
Increased by 39.97%
Revenue Next Year
53.66M
from 35.58M
Increased by 50.80%
EPS This Year
-3.95
from -3.47
EPS Next Year
-3.85
from -3.95
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 63.0M | 89.3M | |||
| Avg | 35.6M | 53.7M | |||
| Low | 14.7M | 24.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 147.8% | 150.8% | |||
| Avg | 40.0% | 50.8% | |||
| Low | -42.2% | -30.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.60 | -2.03 | |||
| Avg | -3.95 | -3.85 | |||
| Low | -4.56 | -4.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.